News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
738,750 Results
Type
Article (43718)
Company Profile (473)
Press Release (694547)
Multimedia
Podcasts (123)
Webinars (20)
Section
Business (209330)
Career Advice (2040)
Deals (36152)
Drug Delivery (119)
Drug Development (83989)
Employer Resources (174)
FDA (16703)
Job Trends (15189)
News (354205)
Policy (33288)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2660)
Accelerated approval (37)
Adcomms (28)
Allergies (146)
Alliances (51113)
ALS (179)
Alzheimer's disease (1735)
Antibody-drug conjugate (ADC) (334)
Approvals (16947)
Artificial intelligence (550)
Autoimmune disease (166)
Automation (41)
Bankruptcy (373)
Best Places to Work (11840)
BIOSECURE Act (20)
Biosimilars (196)
Biotechnology (331)
Bladder cancer (163)
Brain cancer (61)
Breast cancer (655)
Cancer (4978)
Cardiovascular disease (423)
Career advice (1725)
Career pathing (38)
CAR-T (295)
CDC (47)
Celiac Disease (2)
Cell therapy (789)
Cervical cancer (36)
Clinical research (71506)
Collaboration (1816)
Company closure (4)
Compensation (1194)
Complete response letters (67)
COVID-19 (2774)
CRISPR (102)
C-suite (902)
Cystic fibrosis (152)
Data (6374)
Decentralized trials (2)
Denatured (39)
Depression (145)
Diabetes (507)
Diagnostics (6765)
Digital health (50)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (272)
Drug pricing (196)
Drug shortages (29)
Duchenne muscular dystrophy (247)
Earnings (91519)
Editorial (61)
Employer branding (21)
Employer resources (153)
Events (121130)
Executive appointments (1015)
FDA (19888)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (11)
Frontotemporal dementia (24)
Funding (1546)
Gene editing (218)
Generative AI (45)
Gene therapy (651)
GLP-1 (1011)
Government (4764)
Grass and pollen (6)
Guidances (385)
Healthcare (19213)
HIV (64)
Huntington's disease (47)
IgA nephropathy (87)
Immunology and inflammation (280)
Immuno-oncology (62)
Indications (116)
Infectious disease (3054)
Inflammatory bowel disease (202)
Inflation Reduction Act (17)
Influenza (121)
Intellectual property (259)
Interviews (315)
IPO (16933)
IRA (53)
Job creations (3713)
Job search strategy (1440)
JPM (66)
Kidney cancer (16)
Labor market (86)
Layoffs (582)
Leadership (34)
Legal (8028)
Liver cancer (93)
Longevity (14)
Lung cancer (674)
Lymphoma (385)
Machine learning (43)
Management (59)
Manufacturing (824)
MASH (172)
Medical device (13931)
Medtech (13986)
Mergers & acquisitions (20306)
Metabolic disorders (1327)
Multiple sclerosis (168)
NASH (19)
Neurodegenerative disease (345)
Neuropsychiatric disorders (97)
Neuroscience (3041)
Neurotech (1)
NextGen: Class of 2026 (6770)
Non-profit (4586)
Now hiring (67)
Obesity (636)
Opinion (285)
Ovarian cancer (169)
Pain (205)
Pancreatic cancer (236)
Parkinson's disease (297)
Partnered (34)
Patents (511)
Patient recruitment (510)
Peanut (57)
People (60357)
Pharmaceutical (85)
Pharmacy benefit managers (30)
Phase 1 (22491)
Phase 2 (31526)
Phase 3 (23304)
Pipeline (5473)
Policy (300)
Postmarket research (2602)
Preclinical (9613)
Press Release (67)
Prostate cancer (247)
Psychedelics (56)
Radiopharmaceuticals (302)
Rare diseases (904)
Real estate (6065)
Recruiting (71)
Regulatory (25067)
Reports (53)
Research institute (2491)
Resumes & cover letters (354)
Rett syndrome (27)
RNA editing (21)
RSV (79)
Schizophrenia (156)
Series A (257)
Series B (202)
Service/supplier (11)
Sickle cell disease (105)
Special edition (27)
Spinal muscular atrophy (162)
Sponsored (43)
Startups (3806)
State (2)
Stomach cancer (18)
Supply chain (107)
Tariffs (85)
The Weekly (82)
Vaccines (1043)
Venture capital (96)
Weight loss (411)
Women's health (94)
Worklife (19)
Date
Today (202)
Last 7 days (642)
Last 30 days (2369)
Last 365 days (30837)
2026 (3915)
2025 (31063)
2024 (36300)
2023 (41015)
2022 (52279)
2021 (56767)
2020 (54922)
2019 (47420)
2018 (35699)
2017 (33026)
2016 (32347)
2015 (38396)
2014 (32187)
2013 (27115)
2012 (29225)
2011 (29867)
2010 (27997)
Location
Africa (754)
Alabama (89)
Alaska (7)
Arizona (318)
Arkansas (14)
Asia (40725)
Australia (6767)
California (11590)
Canada (3331)
China (1146)
Colorado (489)
Connecticut (502)
Delaware (342)
Europe (89314)
Florida (1716)
Georgia (362)
Hawaii (3)
Idaho (61)
Illinois (894)
India (68)
Indiana (530)
Iowa (24)
Japan (441)
Kansas (131)
Kentucky (41)
Louisiana (27)
Maine (72)
Maryland (1413)
Massachusetts (8414)
Michigan (330)
Minnesota (643)
Mississippi (5)
Missouri (130)
Montana (34)
Nebraska (28)
Nevada (122)
New Hampshire (83)
New Jersey (3081)
New Mexico (31)
New York (3037)
North Carolina (1550)
North Dakota (9)
Northern California (5646)
Ohio (340)
Oklahoma (21)
Oregon (45)
Pennsylvania (2322)
Puerto Rico (24)
Rhode Island (49)
South America (1122)
South Carolina (66)
South Dakota (1)
Southern California (4498)
Tennessee (178)
Texas (1781)
United States (41216)
Utah (343)
Vermont (1)
Virginia (272)
Washington D.C. (82)
Washington State (961)
West Virginia (4)
Wisconsin (116)
Wyoming (2)
738,750 Results for "ptc therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
PTC Therapeutics Announces Health Canada Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU)
December 10, 2025
·
3 min read
Rare diseases
FDA Rejects PTC Therapeutics’ Friedreich’s Ataxia Drug
The small molecule, vatiquinone, had already flunked a Phase III trial, but the company pushed ahead with an approval bid anyway.
August 19, 2025
·
1 min read
·
Dan Samorodnitsky
Pharm Country
PTC Therapeutics to Participate at Upcoming May 2024 Investor Conference
PTC Therapeutics, Inc. announced that the company will present a company overview at the following conference.
May 29, 2024
·
1 min read
Pharm Country
PTC Therapeutics Announces Validation of Sepiapterin European MAA
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the sepiapterin MAA for PKU has been validated and accepted for review by the EMA.
May 28, 2024
·
6 min read
Pharm Country
PTC Therapeutics to Participate at Upcoming May 2024 Investor Conferences
PTC Therapeutics, Inc. announced that the company will present a company overview at the following conferences.
May 2, 2024
·
1 min read
Policy
PTC Therapeutics Provides Key Regulatory Updates
PTC Therapeutics, Inc. announced the submission of a BLA to the U.S. FDA for Upstaza™, a gene therapy for the treatment of aromatic L-amino acid decarboxylase deficiency.
March 19, 2024
·
8 min read
Pharm Country
PTC Therapeutics to Participate at Upcoming March 2024 Investor Conferences
PTC Therapeutics, Inc. announced that the company will present a company overview at the following conferences.
February 27, 2024
·
1 min read
Pharm Country
PTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza™
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the FDA has accepted for filing the Biologics License Application (BLA) for Upstaza™ (eladocagene exuparvovec), a gene therapy for the treatment of AADC deficiency.
May 14, 2024
·
6 min read
Business
PTC Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the first quarter ending March 31, 2024.
April 25, 2024
·
14 min read
Huntington’s disease
Novartis Pays Up to $2.9B in Huntington’s Deal With PTC
Monday’s agreement comes days after PTC discontinued the development of another asset, utreloxastat, due to disappointing Phase II data in amyotrophic lateral sclerosis.
December 2, 2024
·
2 min read
·
Tristan Manalac
1 of 73,875
Next
